Lymphoma
Conditions
Keywords
CLL, SLL, Booster, Lymphoma, Vaccines
Brief summary
Background: People with B cell malignancies (blood cancers) often cannot mount a full immune response to infections or certain vaccines. Bruton tyrosine kinase inhibitors (BTKis), which are used to treat blood cancers, may also negatively affect a person s response to certain vaccines. Researchers want to learn more about vaccine responses in people with certain types of blood cancers. The findings may help develop better vaccine strategies for people with these cancers. Objective: To learn how well vaccines work in people who have certain types of blood cancers. Eligibility: Adults aged 18 years or older who have chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia, or certain non-Hodgkin lymphomas. Design: Participants will get one or more vaccines for illnesses such as COVID-19, hepatitis B, and shingles. They can choose which vaccines they receive. They will give a blood sample before they get each vaccine. Some vaccines require a second dose 3-6 weeks later. Participants may give an optional blood sample with the second vaccine dose. About 4 weeks after they finish each vaccine series, they will give another blood sample. They will have 2-3 study visits per vaccine. Participants may receive a booster dose for some vaccines. The booster dose is optional. They will give another blood sample with the booster dose. Participants will have pregnancy tests, if needed. Participants with CLL who receive BTKis may be asked to pause treatment for up to 7 weeks. Participants may give follow-up blood samples up to 2 times a year for 5 years. These blood samples are optional. Participation will last for up to 5 years after each vaccine series is received.
Detailed description
Study Description: This study aims to determine vaccine titers in B-cell malignancies; specifically, in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), or other non-Hodgkin lymphomas (NHL) \[follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphomas (MZLs) and indolent NHL not otherwise specified (NOS)\], or in Waldenstrom Macroglobulinemia (WM). Note: Since CLL and SLL are considered the same disease, CLL/SLL will be referred to as CLL hereafter, unless otherwise specified. Objectives: Primary Objective: Determine vaccine titers following vaccination in patients with B-cell malignancies who are either receiving targeted therapies or not receiving active treatment Secondary Objectives: 1. Determine vaccine titers in patients with CLL that are treatment naive, not receiving active treatment, or receiving targeted therapies 2. Determine whether interruption of Bruton tyrosine kinase inhibitor (BTKi) therapy around the time of vaccination improves vaccine titers in patients with CLL 3. Determine vaccine titers in patients with NHL (FL, MCL, MZL, NHL NOS) or WM that are not receiving active treatment, or receiving targeted therapies Endpoints: The primary efficacy endpoint will be the serologic titer against each administered vaccine following completion of the vaccine series in each study arm
Interventions
BIOLOGICALFluzone
Annual Influenza Vaccine
BIOLOGICALShingrix
Recombinant, adjuvanted Zoster Vaccine (RZV)
BIOLOGICALFlucelvax
Annual Influenza Vaccine
BIOLOGICALAfluria
Annual Influenza Vaccine
BIOLOGICALPREVNAR 13
Pneumococcal Conjugate Vaccine (PCV13)
BIOLOGICALHeplisav -B
Recombinant, adjuvanted Hepatitis (HepB-CpG)
BIOLOGICALPfizer-COVID-19 Vaccine
COVID-19 Vaccine
BIOLOGICALFluLaval
Annual Influenza Vaccine
BIOLOGICALFluarix
Annual Influenza Vaccine
BIOLOGICALPNEUMOVAX 23
Pneumococcal Polysaccharide Vaccine (PPSV23)
DRUGPREVNAR 20
Pneumococcal 20-Valent Conjugate Vaccine (PCV20)
DRUGAREXVY, ABRYSVO
Respiratory Syncytial Virus Vaccine
Sponsors
National Heart, Lung, and Blood Institute (NHLBI)
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* INCLUSION CRITERIA: * Diagnosis of CLL, FL, MCL, MZL, NHL NOS or WM * Must fulfil one of the following criteria to be enrolled in one study arm per vaccine received: 1. Patients with CLL AND one of the following: i. Arm 1: Must be treatment naive (no prior cancer directed therapy) ii. Arm 2: Patients that have received prior cancer directed therapy and are currently not receiving active treatment iii. Arm 3: Must be receiving treatment with a BTKi. This arm is not available to patients receiving the HEPLISAV-B vaccine iv. Arm 4: Must be receiving treatment with a BTKi for \>= 6 months prior to vaccination and be willing to hold their treatment for up to 7 weeks around the time of each vaccination. This arm is not available to patients who have had a prior episode of disease flare during periods of drug hold, or for patients with CLL that is actively progressing. v. Arm 5: Must be receiving treatment with a BCL-2 inhibitor Or 2. Patients with FL, MCL, MZL, NHL NOS or WM AND one of the following: i. Arm 1: Must currently not be receiving active treatment (treatment na(SqrRoot) ve or previously treated) ii. Arm 2: Must be receiving treatment with targeted therapies (e.g. BTKi, BCL-2 inhibitors, PI3K inhibitors, immunomodulatory agents, proteasome inhibitors) * If prior exposure to Hepatitis-B vaccination, must have documentation of negative serologic response * Age \>= 18 years * Able to comprehend the investigational nature of the protocol and provide informed consent
Exclusion criteria
1. Female patients who are currently pregnant 2. History of severe allergic reaction to vaccines 3. Concomitant inherited immunodeficiency 4. Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator s opinion, could compromise the subject s safety or put the study outcomes at undue risk. 5. Receive cytotoxic chemotherapy within 2 weeks prior to vaccination 6. Receive intravenous immunoglobulin (IVIG) within 2 months prior to vaccination 7. Receive anti-CD20 and/or anti-CD19 monoclonal antibody therapy within 6 months prior to vaccination 8. Receive cellular therapy (e.g. CAR-T cells) within 12 months prior to vaccination 9. History of allogeneic stem cell transplantation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serologic response against each administered vaccine following completion of the vaccine series in each study arm | 4 weeks after completing vaccine series | vaccine titer |
Countries
United States
Contacts
CONTACTRachel A Adams
CONTACTAdrian U Wiestner, M.D.
PRINCIPAL_INVESTIGATORAdrian U Wiestner, M.D.
National Heart, Lung, and Blood Institute (NHLBI)
Outcome results
None listed